iPSC-Based Modeling of Variable Clinical Presentation in Hypertrophic Cardiomyopathy
- PMID: 37317833
- DOI: 10.1161/CIRCRESAHA.122.321951
iPSC-Based Modeling of Variable Clinical Presentation in Hypertrophic Cardiomyopathy
Abstract
Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and a frequent cause of heart failure and sudden cardiac death. Our understanding of the genetic bases and pathogenic mechanisms underlying HCM has improved significantly in the recent past, but the combined effect of various pathogenic gene variants and the influence of genetic modifiers in disease manifestation are very poorly understood. Here, we set out to investigate genotype-phenotype relationships in 2 siblings with an extensive family history of HCM, both carrying a pathogenic truncating variant in the MYBPC3 gene (p.Lys600Asnfs*2), but who exhibited highly divergent clinical manifestations.
Methods: We used a combination of induced pluripotent stem cell (iPSC)-based disease modeling and CRISPR (clustered regularly interspersed short palindromic repeats)/Cas9 (CRISPR-associated protein 9)-mediated genome editing to generate patient-specific cardiomyocytes (iPSC-CMs) and isogenic controls lacking the pathogenic MYBPC3 variant.
Results: Mutant iPSC-CMs developed impaired mitochondrial bioenergetics, which was dependent on the presence of the mutation. Moreover, we could detect altered excitation-contraction coupling in iPSC-CMs from the severely affected individual. The pathogenic MYBPC3 variant was found to be necessary, but not sufficient, to induce iPSC-CM hyperexcitability, suggesting the presence of additional genetic modifiers. Whole-exome sequencing of the mutant carriers identified a variant of unknown significance in the MYH7 gene (p.Ile1927Phe) uniquely present in the individual with severe HCM. We finally assessed the pathogenicity of this variant of unknown significance by functionally evaluating iPSC-CMs after editing the variant.
Conclusions: Our results indicate that the p.Ile1927Phe variant of unknown significance in MYH7 can be considered as a modifier of HCM expressivity when found in combination with truncating variants in MYBPC3. Overall, our studies show that iPSC-based modeling of clinically discordant subjects provides a unique platform to functionally assess the effect of genetic modifiers.
Keywords: energy metabolism; mutation; phenotype; sibling; studies.
Conflict of interest statement
Similar articles
-
Generation of Isogenic iPSC Lines for Studying the Effect of the p.N515del (c.1543_1545delAAC) Variant on MYBPC3 Function and Hypertrophic Cardiomyopathy Pathogenesis.Int J Mol Sci. 2024 Nov 30;25(23):12900. doi: 10.3390/ijms252312900. Int J Mol Sci. 2024. PMID: 39684611 Free PMC article.
-
Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.Circulation. 2018 Dec 4;138(23):2666-2681. doi: 10.1161/CIRCULATIONAHA.117.032273. Circulation. 2018. PMID: 29914921 Free PMC article.
-
A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.Circulation. 2019 Feb 5;139(6):799-811. doi: 10.1161/CIRCULATIONAHA.118.034624. Circulation. 2019. PMID: 30586709 Free PMC article.
-
Characterization of cardiac metabolism in iPSC-derived cardiomyocytes: lessons from maturation and disease modeling.Stem Cell Res Ther. 2022 Jul 23;13(1):332. doi: 10.1186/s13287-022-03021-9. Stem Cell Res Ther. 2022. PMID: 35870954 Free PMC article. Review.
-
Modeling hypertrophic cardiomyopathy with human cardiomyocytes derived from induced pluripotent stem cells.Stem Cell Res Ther. 2022 Jun 3;13(1):232. doi: 10.1186/s13287-022-02905-0. Stem Cell Res Ther. 2022. PMID: 35659761 Free PMC article. Review.
Cited by
-
Toward the latest advancements in cardiac regeneration using induced pluripotent stem cells (iPSCs) technology: approaches and challenges.J Transl Med. 2024 Aug 22;22(1):783. doi: 10.1186/s12967-024-05499-8. J Transl Med. 2024. PMID: 39175068 Free PMC article. Review.
-
Crispr-Based Editing of Human Pluripotent Stem Cells for Disease Modeling.Stem Cell Rev Rep. 2024 Jul;20(5):1151-1161. doi: 10.1007/s12015-024-10713-7. Epub 2024 Apr 2. Stem Cell Rev Rep. 2024. PMID: 38564139
-
Cell and tissue reprogramming: Unlocking a new era in medical drug discovery.Pharmacol Rev. 2025 Jun 26;77(5):100077. doi: 10.1016/j.pharmr.2025.100077. Online ahead of print. Pharmacol Rev. 2025. PMID: 40683107 Free PMC article. Review.
-
Genetic landscape of phospholamban cardiomyopathies.Front Cell Dev Biol. 2025 Jun 10;13:1626242. doi: 10.3389/fcell.2025.1626242. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40556736 Free PMC article. Review.
-
Generation of Isogenic iPSC Lines for Studying the Effect of the p.N515del (c.1543_1545delAAC) Variant on MYBPC3 Function and Hypertrophic Cardiomyopathy Pathogenesis.Int J Mol Sci. 2024 Nov 30;25(23):12900. doi: 10.3390/ijms252312900. Int J Mol Sci. 2024. PMID: 39684611 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous